CompletedPhase 4

Tranexamic Acid in Abdominoplasty.

Poland60 participantsStarted 2023-10-17

Plain-language summary

The investigators prepared a novel tranexamic acid (TXA) study designed to estimate the quantity of blood loss in patients undergoing abdominoplasty surgery. This study aims to quantify blood loss during abdominoplasty with and without TXA. The central hypothesis is that TXA administration reduces blood loss and fibrinolysis in patients undergoing abdominoplasty surgery.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Scheduled abdominoplasty * ASA 1 or 2 * age \>18 and \<75 years Exclusion Criteria: * BMI \<20 or \>35 kg/m2 * ASA 3 or \> 3 * medical history of thromboembolism * history of hematological disease * treatment with aspirin 14 days before the procedure * treatment with anticoagulants 5 days before the procedure * epilepsy * allergy to tranexamic acid * coagulation disorders

What they're measuring

Blood loss volume

Timeframe: 24 hours after surgery

Trial details

NCT IDNCT06086444

SponsorPoznan University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-10

View on ClinicalTrials.gov More Abdominal Wall Defect trials